Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Generex Biotechnology Corp. (GNBTQ) Message Board

Fuse 10q Three Months Ended March 31, 2019, Com

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36563
(Total Views: 450)
Posted On: 05/07/2019 11:17:53 PM
Posted By: rjs9787
Fuse 10q

Three Months Ended March 31, 2019, Compared to Three Months Ended March 31, 2018
Net Revenues
For the three months ended March 31, 2019, net revenues were $4,770,659 compared to $6,004,048 for the three months ended March 31, 2018, which is a decrease of $1,233,389 or approximately twenty-one percent (21%).
For the three months ended March 31, 2019, Retail Cases increased by one percent (1%) compared to the three months ended March 31, 2018. However, revenues from Retail Cases for the three months ended March 31, 2019, decreased by fourteen percent (14%) compared to revenues from Retail Cases for the three months ended March 31, 2018. We believe this fourteen percent (14%) decrease in revenues from Retail Cases is primarily driven by a reduction in average revenue per Retail Case.
Due to our business strategy of focusing our business on Retail Cases, our Wholesale Cases declined by thirty-three percent (33%) for the three months ended March 31, 2019, compared to Wholesale Cases during the three months ended March 31, 2018. Accordingly, revenues from Wholesale Cases for the three months ended March 31, 2019, declined by twenty-six percent (26%) compared to revenues from Wholesale Cases for the period ended March 31, 2018.
As discussed above in “Current Trends and Outlook,” we believe that as our industry faces increased pricing pressures, we will need to focus on increased volume of Cases to maintain gross profit levels. We intend to increase our Case volume for the three remaining quarters of 2019 by focusing our operations on Retail Cases with our existing retail customer base and adding new retail customers.


(0)
(0)




Generex Biotechnology Corp. (GNBTQ) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us